Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Heery Website

Christopher R. Heery, M.D.

Selected Publications

1)  Gulley JL, Madan RA, Tsang KY, Jochems C, Marté JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, Heery CR, Schlom J.
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.
Cancer Immunol Res. 2: 133-41, 2014.
[Journal]
2)  Gulley JL, Heery CR, Madan RA, Walter BA, Merino MJ, Dahut WL, Tsang KY, Schlom J, Pinto PA.
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
Cancer Immunol. Immunother. 62: 1521-31, 2013.
[Journal]
3)  Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, Madan RA.
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
Cancer Immunol. Immunother. 63: 225-34, 2014.
[Journal]
4)  Farsaci B, Jochems C, Grenga I, Donahue RN, Tucker JA, Pinto PA, Merino MJ, Heery CR, Madan RA, Gulley JL, Schlom J.
Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.
Int. J. Cancer. 135: 862-70, 2014.
[Journal]
5)  Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL.
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.
Clin. Cancer Res. 17: 7164-73, 2011.
[Journal]
6)  Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL.
Therapeutic cancer vaccines.
Adv. Cancer Res. 121: 67-124, 2014.
[Journal]
7)  Gulley JL, Madan RA, Heery CR.
Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer.
Am Soc Clin Oncol Educ Book. 166-70, 2013.
[Journal]
8)  Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL.
Clinical evaluation of TRICOM vector therapeutic cancer vaccines.
Semin. Oncol. 39: 296-304, 2012.
[Journal]
9)  Madan RA, Heery CR, Gulley JL.
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity.
Oncoimmunology. 1: 1167-1168, 2012.
[Journal]
10)  Heery CR, Hodge JW, Gulley JL.
Combining radiation and therapeutic cancer vaccines: a synergistic approach.
Breast Cancer Management. 1: 325-335, 2012.
[Journal]
11)  Bilusic M, Heery C, Madan RA.
Immunotherapy in prostate cancer: emerging strategies against a formidable foe.
Vaccine. 29: 6485-97, 2011.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 6/27/2014.